
Intellectual Property - March 26, 2019
LIDDS’ technology receives US patent
The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid technology patent. The same patent was approved by the European Patent Office in 2018. With this new US patent, the NanoZolid technology will be protected until 2037 in both Europe and in the US. LIDDS will pursue additional patent […]

Pharma Business - March 5, 2019
Mini-interview: Monica Wallter, CEO of LIDDS
The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. What’s next for LIDDS and what results can we […]